• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Efficacy and safety of newly developed preservativefree latanoprost 0.005% eye drops versus preserved latanoprost 0.005% in open angle glaucoma and ocular hypertension: 12-week results of a randomized,multicenter, controlled phase III trial

    2021-11-08 01:45:48JoonMoKimKyungRimSungJiWoongLeeHaksuKyungSeungsooRhoChanYunKim
    International Journal of Ophthalmology 2021年10期

    Joon Mo Kim, Kyung Rim Sung, Ji Woong Lee, Haksu Kyung, Seungsoo Rho, Chan Yun Kim

    1Department of Ophthalmology, Kangbuk Samsung Hospital,Sungkyunkwan University School of Medicine, Seoul 03181,Republic of Korea

    2Department of Ophthalmology, Seoul Asan Medical Center,Ulsan University College of Medicine, Seoul 05505, Republic of Korea

    3Department of Ophthalmology, Pusan National University Hospital, Pusan National University Medical School, Busan 49241, Republic of Korea

    4Department of Ophthalmology, National Medical Center,Seoul 04564, Republic of Korea

    5Department of Ophthalmology, CHA Bundang Medical Center, CHA University, Seongnam 13496, Republic of Korea

    6Department of Ophthalmology, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea

    Abstract

    ● KEYWORDS: latanoprost; benzalkonium chloride;intraocular pressure; preservative-free;

    INTRODUCTION

    Glaucoma is a major cause of irreversible blindness worldwide, and 111.8 million patients are expected globally by 2040[1]. Although many factors have been suggested as causes of glaucoma development, intraocular pressure (IOP)is still thought to be a major factor in the development and progression of glaucoma[2-3]. Many studies have reported that treatments that lower IOP decrease glaucoma progression[4-8].To date, control of IOP is the only proven way to suppress the progression of glaucoma. Therefore, IOP reduction remains the cornerstone of glaucoma management[9].

    Prostaglandin analogue (PGA) has been used more and more frequently as it is preferred as a first-time glaucoma drug,which is effective and has less severe systemic side effects and requires only one dose per day[10]. Among the various PGAs,latanoprost, which was first developed, is the most widely used in ocular hypertension (OHT) and primary open angle glaucoma (POAG) due to its good effect and less side effects such as conjunctival hyperemia compared to other PGAs[10-12].However, latanoprost eye drops currently commonly used have a high concentration of benzalkonium chloride (BAK)and contain sodium phosphate, which could cause side effects such as conjunctivitis and corneal surface epithelial toxicity when administered for a long time[13-14]. Ocular surface changes that occur using prostaglandin eye drops with BAK can be significantly related to the concentration-dependent cytotoxicity of these preservatives[15]. In addition, the side effects of BAK may have a greater impact on glaucoma patients who need to use their medicine for life. On the other hand, in the case of preservative-free (PF) latanoprost, few apoptosis cells were found in the superficial layer of the corneal epithelium in human and toxic animal models[15-16]. Therefore, in the 2009 EMA guideline, the European Glaucoma Society recommends PF products for patients with glaucoma who have dry eye or ocular surface diseases[17].

    Recently, a PF latanoprost generic eye drop was developed,TJO-002 (Xalost?S in Korea). TJO-002 has been formulated to have several presumed advantages over the conventional latanoprost preparation, which contains BAK. Polyoxyl 40 hydrogenated castor oil, carbomer (mucoadhesive polymer),and high-concentration sorbitol were used to promote substance stabilization and penetration into the eyeball instead of BAK and sodium phosphate. In order to improve the tolerability,instead of having a pH of 5.5 like the conventional latanoprost formulation [Xalatan?], TJO-002 has a physiologically active pH range of 7.0-7.3. This new formulation focuses on high stability, tolerability and non-inferior efficacy compared with the conventional formulation. This study aimed to compare TJO-002 with BAK-preserved latanoprost for IOP-lowering efficacy, safety and tolerability in patients with POAG/OHT.

    SUBJECTS AND METHODS

    Ethical Approval This study was approved by the Institutional Review Board of each center. This study was performed according to the tenets of the Helsinki Declaration and compliance with the International Conference on Harmonization Good Clinical Practice guidelines and Korean regulations. All patients were fully informed and provided written consent for participation before enrollment.

    Study Design and Patients The study was a multicenter,randomized, investigator-masked, active control, and parallelgroup phase III clinical trial (NCT03419975). It was conducted in 17 clinical sites from 3 December 2015 to 5 March 2018.This study compared the newly developed PF latanoprost formulation TJO-002 (Taejoon Pharmaceutical Co., Ltd.,Yongin, Republic of Korea) with BAK-preserved latanoprost(Xalatan?, Pfizer Inc., Belgium NV Puurs, Belgium) during a 3-month treatment period. Given that TJO-002 is supplied in single dose units and BAK latanoprost in bottles, the investigational drug was managed by dividing the blind part and the unblind part and the investigator was blind part so that they could not know which eyedrop to be administered, only the investigator measuring IOP during the ophthalmological examination was masked to the study medication.

    This study enrolled adult patients (≥19 years of age) with POAG/OHT. Patients with an IOP of 21 to 35 mm Hg at 9a.m.(±1h) in eligible eyes after a run-in period were randomized 1:1 and assigned the treatment schedule with TJO-002 or BAK latanoprost administered as one drop daily in each eye.We excluded the patients who had 20/80 or below of bestcorrected visual acuity on the Snellen chart and medical history of chronic intraocular inflammation in progress or within 3mo prior to screening. Patients who needed to use contact lenses during the clinical study and women who were pregnant, planning to become pregnant, currently nursing,of childbearing potential, or not using a reliable form of contraception were also excluded. Patients were randomized if IOP was >21 mm Hg in the eligible eye(s). If both eyes met the criteria, the eye with the higher IOP was selected. If the IOP was equal, the right eye was selected. Patients were instructed to instill one drop in each eye once daily in the evening(9p.m.±1h) and were scheduled for follow-up visits at 4, 8,and 12wk. The subjects were asked to keep a daily indication of whether or not to take an investigational drug in their diary table every time they administered, and were asked to answer the symptoms that they felt bad for the last week before the visit.

    Assessment Parameters The primary efficacy variable was the change in IOP between baseline and 12wk in the study eye.Diurnal IOP (average of 2 consecutive IOP measurements)was measured at the same hour (9a.m.±1h and 5p.m.±1h)at each visit using a calibrated Goldmann applanation tonometer(Figure 1). All patients underwent ocular examinations, including visual acuity assessment, slit lamp biomicroscopy, gonioscopy,standard automated perimetry, and ophthalmoscopy. IOP was measured (at 9a.m.and 5p.m.) during the baseline visit and at the 8-week and 12-week visits after eye-drop instillation. At the 4-week visit after instillation, IOP was measured only at 9a.m. Safety outcome measures included adverse events (AEs) reporting, visual acuity, and tolerability.

    Table 1 Patient demographics

    Figure 1 Study schedule Eligible patients were randomized to either the TJO-002 group or the BAK-preserved latanoprost group.

    Tolerability was evaluated with the frequency and percentage of distributions of severity level by symptoms in each group after administration at 4, 8, and 12wk with questionnaire in the blind part (investigator). The symptoms checked during follow-up visits were pruritus, burning/stinging, blurred vision,sticky eye sensation, eye dryness sensation, and foreign body sensation. Each of symptoms was written by investigator about the symptoms subjects feel after instilling investigational drugs. The tolerability was evaluated by checking how the symptoms were changed based on the symptoms of the worst degree among the records written about the symptoms of the investigational drug administration for a week before visit.

    Statistical Analysis The primary objective was to demonstrate the non-inferiority of the trial drug to the control drug in terms of diurnal IOP variation after the administration of the drugs for 12wk. If the maximum value of the confidence intervals was less than 1.5 mm Hg, the trial group was judged to be non-inferior to the control group[18]. The upper limit of noninferiority was set at 1.5 mm Hg as this is the standard acceptance level for noninferiority in glaucoma studies[19-21].The adjusted average and standard error of the IOP variations in the trial and control groups, the difference between the average and adjusted average, 95% two-tailed confidence intervals of adjusted average difference andP-values were calculated by conducting an analysis of covariation(ANCOVA) with baseline IOP as covariate and treatment as a parameter for IOP variations. Additionally, if there were any statistically significant variables among sex, ages, and BMI distribution, an ANCOVA was performed that corrected for these variables as a sensitivity analysis. Statistical analyses were performed using SAS v9.2 (SAS Institute, Cary, NC,USA). Tolerability was evaluated with the frequency and percentage of severity level distribution for each symptom in each group at 4, 8, and 12wk, and those differences between the groups were evaluated through Chi-square tests or Fisher’s exact tests. When there was a missing value, the last observation carried forward method was used.

    RESULTS

    Among 196 consenting subjects, 52 people were excluded(38 patients with “Deviation of inclusion/exclusion criteria”,13 with “Consent withdrawal” and 1 with “Other”), and 144 people were randomized. The full description of the inclusion and exclusion steps is outlined in Figure 2.

    Demographic Characteristics There were 78.38% menvs21.62% women in the TJO-002 group and 60.00% men vs 40.00% women in the BAK latanoprost group. The sex ratios between the two groups were statistically significantly different(P=0.0167). There were no differences in other characteristics between the two groups (P>0.05; Table 1).

    Efficacy Twelve weeks after initiation of drug administration,the mean diurnal IOP change was -7.21±3.10 mm Hg in the TJO-002 group and -7.02±3.17 mm Hg in the BAK latanoprost group. Both groups showed a statistically significant decrease of average diurnal IOP (P<0.0001) compared with baseline,but there was no significant difference in the follow-up IOPs and IOP changes between the two groups (Table 2).

    Table 3 shows the change in the mean IOP at 9a.m.of each follow-up visit after drug administration compared to baseline.Both groups showed a statistically significant decrease in IOP at each follow-up visit (P<0.0001 each) from the baseline IOPs, but there was no statistically significant difference in the follow-up IOPs between the two groups.

    Although the IOP in the TJO-002 group was less than that of the BAK latanoprost group at 9a.m.at 8wk after the beginning of the instillation, the difference was not statistically significant(P=0.06). Table 4 shows diurnal IOP fluctuation from 9a.m.to 5p.m.at 8 and 12wk of drug administration compared to that of baseline. The IOP fluctuations of the TJO-002 group were less than those of the BAK latanoprost group during the entire study period. However, the difference did not reach statistical significance except by 8wk after instillation (P<0.0342).

    Figure 2 Study progress diagram FAS: Full analysis set; PPS: Per protocol set.

    Table 2 Diurnal IOP by measurement time at baseline and 12wk of the treatment groups by ITT and PP mean±SD, mm Hg

    Table 3 IOP by measurement time at baseline, 4, 8 and 12wk of the treatment groups by ITT and PP mean±SD, mm Hg

    Table 4 Diurnal IOP fluctuation from 9 a.m. to 5 p.m. at baseline, 8 and 12wk of the treatment groups by ITT and PP mean±SD, mm Hg

    Table 5 Number of patients with ocular adverse events and drug-associated systemic adverse events

    Safety Table 5 shows ocular and systemic AEs in both groups. The incidence of AEs regardless of relationship with the study medications was 24.66% (18/73 people, 26 cases)in the TJO-002 group and 25.00% (17/68, 27 cases) in the BAK latanoprost group; there was no statistically significant difference between the groups (P=0.9625). The incidence of“Eye disorders” in the BAK latanoprost group was 10.29%(7/68 people, 10 cases), and in the TJO-002 group, it was 12.33% (9/73, 13 cases). The difference in incidence between the groups was not statistically significant (P=0.7035). Drugassociated systemic adverse events other than ocular adverse events included nasopharyngitis (1) and cerebral infarction (1)in the TJO-002 group and atypical mycobacterial pneumonia(1), bronchiolitis (1), sinusitis (1), acute myeloid leukemia (1)and rash (1) in the BAK latanoprost group. However, those AE did not appear to be associated with the study medications.

    Tolerability Severity of pruritus, burning/stinging, blurred vision, sticky eye sensation, eye dryness sensation, and foreign body sensation were compared between the two groups at 4-, 8-, and 12-week visits in the PP population among them,the severity of pruritus (12wk:P=0.0117), burning/stinging(4wk:P=0.0256, 8wk:P=0.0003, 12wk:P<0.0001), and sticky eye sensation (8wk:P=0.0010) were significantly different between the groups. TJO-002 showed a statistically significantly better tolerability than BAK latanoprost in three categories (Table 6).

    DISCUSSION

    In this randomized, investigator-masked multicenter trial in patients with POAG/OHT, the newly formulated PF latanoprost, TJO-002, showed similar efficacy and better tolerability compared with BAK latanoprost. In terms of efficacy, TJO-002 was non-inferior to BAK latanoprost in lowering IOP at all study follow-up assessment points (week 4, 8, and 12). In terms of tolerability, TJO-002 showed lower incidence of pruritus, burning/stinging, and sticky eye sensation than BAK latanoprost for the study duration.There was no difference in systemic side effects between the two groups. TJO-002 appeared to have better efficacy and tolerability compared with BAK latanoprost eyedrops.

    Measured IOPs were significantly reduced at all follow-up periods from baseline in the groups, and neither the magnitudenor the distribution of the IOP reduction at any visits were statistically different between the two groups. When the IOP measured at 9a.m.was analyzed separately, as it approximates the time of maximal IOP reduction by both medications, it was decreased and maintained for the entire duration of the study.This means that TJO-002 was at least non-inferior to BAK latanoprost in terms of the ability to lower IOP. The reduction of mean IOP at 9a.m.of the last visit compared with baseline was -8.13 mm Hg (33.16%) for TJO-002 and -7.43 mm Hg(31.05%) for BAK latanoprost, which was consistent with the range of the optimal IOP reduction associated with latanoprost 0.005% (approximately 28%-31%) reported previously[22-24].Aspberget al[22]reported that latanoprost was associated with a 28% decrease from the baseline IOP. These results are in agreement with the result of a study in which the IOPlowering efficacy of latanoprost was not dependent on the presence of BAK. Pellinen and Lokkila[25]demonstrated comparable corneal penetration of preserved and PF tafluprost in the aqueous humor of rabbits. Aiharaet al[26]reported that fewer ocular surface complications without significant IOP changes were observed with BAK-free travoprost than with BAK latanoprost, with a reduced prevalence of superficial punctate keratitis and less hyperemia, in a long-term 12-month prospective study. Harasymowyczet al[23]reported that PF latanoprost showed the same efficacy, along with improved local tolerance, compared with BAK latanoprost.

    Table 6 Number of patients with symptoms categorized by severity level comparing the TJO-002 group and the BAK latanoprost group n (%)

    Considering the importance of adherence and the fact that glaucoma requires long-term treatment, local ocular tolerability as well as efficacy is an important factor in preserving the quality of life in patients with glaucoma. In this study, TJO-002 showed better tolerability compared with BAK latanoprost, in terms of pruritus, burning/stinging, and sticky eye sensation.

    There are several presumed reasons for the favorable tolerability of TJO-002. One may be the absence of BAK. While BAK is a commonly used preservative in ophthalmic eye drops,its ocular toxicity is well known. Some studies have shown ocular surface damage, including inflammatory and toxic effects, associated with BAK[14,27-28]. Martinez-de-la-Casaet al[29]reported that the preservative appeared to have an impact on tear cytokine levels. Latanoprost with BAK increased the levels of interleukin, basic fibroblast growth factor, plateletderived growth factor, and tumor necrosis factor-α in tear film. Baudouinet al[28]also suggested that BAK in topical eye drops induces tear film instability, conjunctival inflammation,subconjunctival fibrosis, epithelial apoptosis, and corneal surface impairment. Long-term use of BAK could lead to apoptosis of conjunctival cells and chronic conjunctival inflammation[30]. Furthermore, Desbenoitet al[31]reported that BAK was found in the iris, lens capsule, and trabecular meshwork tissue of rabbits after topical exposure, thus suggesting the penetration of BAK into deep ocular structures.Pisellaet al[32]demonstrated that removal of preservative from timolol ophthalmic solution was associated with improvement of corneal epithelial barrier function, prevention of ocular surface inflammation, and reduction of complaints. Yanget al[33]suggested that topical latanoprost treatment itself could induce dry eyeviainflammation. They reported the effects of latanoprost in mice: it decreased tear production,induced conjunctival goblet cell loss, disrupted the corneal epithelial barrier, and promoted cell apoptosis in the ocular surface. Therefore, latanoprost itself may cause ocular surface problems, and BAK can further aggravate that problem. The new BAK-free formulation of latanoprost in this study, TJO-002,appeared to minimize the discomfort by eliminating BAK toxicity.Another reason may be the ocular tissue-friendly composition of TJO-002, which includes carbomer and sorbitol as the excipient. Carbomer has been widely used for artificial tears[30].Carbomers are anionic polymers and strongly interact with anionic mucin[34]. This mucoadhesive interaction causes carbomer-based formulations to bind with the mucin layer to prolong adhesion[35]. Reports have demonstrated that the ocular retention time of carbomer gel was significantly longer than that of other low-viscosity eye drops[36-37]. In a previous study,when compared to sodium hyaluronate, carbomer showed equivalent therapeutic effects on symptom severity in moderate dry eye[37]. The properties of carbomer seem to play a role in reducing ocular AEs. Furthermore, due to the characteristics of the carbomer, latanoprost may stay on the surface of the eye longer, possibly resulting in a better IOP reduction. The IOP at 9a.m.after 8wk in the TJO-002 group was lower than that in the BAK latanoprost group. Sorbitol is used to enhance the stability of the topical composition in TJO-002.In a 4-week test of stability under severe conditions (55°C,relative humidity 75%), the main ingredient, latanoprost,was maintained without loss. This result showed that the latanoprost preparation containing sorbitol was kept more stable than the preparation without sorbitol (data not shown here). Sorbitol appeared to maintain the stability of TJO-002 at room temperature for 3y. In addition, the appropriate pH for activation and maintenance of TJO-002 is pH 7.0-7.3, at which TJO-002 is neutral, while that of BAK-preserved latanoprost used in this study (Xalatan?, Pfizer Inc., Belgium NV Puurs,Belgium) is pH 5.5. This may be one of the reasons why there is less tingling sensation with TJO-002 than with BAK latanoprost.Gonneringet al[38]showed that the optimal pH range to prevent corneal damage is 6.5 to 8.5, which includes the pH of lacrimal fluid (approximately pH 7.4). Although corneas perfused at pH 5.5 showed changes in endothelial morphology, those perfused at pH values of 7.0, 8.0, and 8.5 maintained normal endothelial morphology[38]. While conjunctival hyperemia was more common in TJO-002 (3vs1). Considering the absence of stimulation by BAK, it was expected to appear less, but the opposite result was obtained. The exact reason for this is not known. In our opinion, the carbomer contained in TJO-002 may be the result of prolonging the hyperemia effect of latanoprost by causing latanoprost to stay in the conjunctival sac for a long time. Severe foreign body sensation was shown in 2 cases of TJO-002 at 4wk after instillation and were lost over time, but in BAK latanoprost, severe case was shown at 12wk. Further study is needed.

    Despite various efforts, this study has several limitations.First, there was no objective examination for ocular surface evaluation, such as tear film break-up testing and corneal/conjunctival staining evaluations. Second, the study was performed using data from one ethnic group; thus, results may not be applicable to other ethnic groups. Third, we did not evaluate all adverse effects of prostaglandin analogue(e.g.,lid pigmentation, deepening of upper eyelid sulcus, and growth of eyelashes) due to the relatively short follow-up duration. Fourth, other ingredients in addition to BAK may have been involved, but comparisons were not made. Since not all of the component of two drugs are the same except for BAK, all other ingredients in the drug may be involved. Fifth,our study conducted a relatively short follow-up duration,12wk. Considering that responses may vary from person to person, the duration of the study may not be appropriate.Further longterm study is needed. Sixth, we did not measure the 24-hour IOP variation, but only examined IOP twice in a day to estimate a certain daily change. However, despite the above limitations, we consider that we sufficiently evaluated and compared TJO-002, PF latanoprost, with conventional latanoprost containing preservative in terms of IOP reduction and ocular surface adverse effects. Finally, compared to previous studies, the subjects in our study are more male and have a relatively young average age. Other similar studies show that the average age is mostly over 60, with similar sex ratios or more female than male[39-42]. However, since our study is a multicenter study, and we have not tried to control the sex ratio of patients, it is not known why this structure was established. Considering the possible reasons, our study was performed in tertiary hospital and general hospitals. These hospitals in Korea are located in large cities, and residents of large cities and office workers around them participated in the study, so it seems that there were relatively more males and younger people than other studies. In addition, male have a higher prevalence of glaucoma than female in Korea[43]. It will be difficult to put our study on the same line with other existing studies and compare it, but it will be a good reference considering age and gender.

    In conclusion, PF latanoprost generic, TJO-002, offers a useful alternative to the available prostaglandin analogues containing BAK for the treatment of POAG/OHT and is likely to be associated with fewer ocular surface problems, without any reduction in efficacy. On the basis of our result, PF-latanoprost could be considered as an alternative to conventional latanoprost, especially in patients suffering from pre-existing or concomitant ocular surface diseases. In the future, it is also of interest to study the comparison of the difference between efficacy and safety with and without preservatives in three different prostaglandin analogues in relation to the surface eye effect of PF.

    ACKNOWLEDGEMENTS

    Foundation:Supported by Taejoon Pharmaceutical.

    Conflicts of Interest:Kim JM, None; Sung KR, None;Lee JW, None; Kyung H, None; Rho S, None; Kim CY,None.

    久久99热这里只有精品18| 亚洲成人免费电影在线观看| 看免费av毛片| 精品一区二区三区四区五区乱码| 岛国在线免费视频观看| 99热只有精品国产| 91麻豆精品激情在线观看国产| 国产av在哪里看| 日韩欧美 国产精品| 亚洲av成人一区二区三| 亚洲人成网站高清观看| 国产精品永久免费网站| 国产精品亚洲av一区麻豆| 亚洲欧美激情综合另类| 两性夫妻黄色片| 国模一区二区三区四区视频 | 午夜精品在线福利| 男插女下体视频免费在线播放| 香蕉丝袜av| 成人午夜高清在线视频| 日韩欧美免费精品| 偷拍熟女少妇极品色| 国产欧美日韩精品亚洲av| 免费av毛片视频| 中文字幕人成人乱码亚洲影| 国产精品综合久久久久久久免费| 亚洲成人久久性| 亚洲人成网站在线播放欧美日韩| av天堂中文字幕网| 久久香蕉精品热| 久久精品91蜜桃| 三级国产精品欧美在线观看 | 嫩草影院入口| 最近最新中文字幕大全免费视频| 九九热线精品视视频播放| 亚洲国产欧美人成| 97超视频在线观看视频| 黄片小视频在线播放| 一区福利在线观看| 国产探花在线观看一区二区| 蜜桃久久精品国产亚洲av| 老司机午夜福利在线观看视频| aaaaa片日本免费| 夜夜夜夜夜久久久久| 久久草成人影院| 成人鲁丝片一二三区免费| 女人被狂操c到高潮| 欧美极品一区二区三区四区| 老司机福利观看| svipshipincom国产片| 亚洲天堂国产精品一区在线| 日本一本二区三区精品| 91老司机精品| 欧美一级a爱片免费观看看| 国产成人av激情在线播放| 精品国产乱子伦一区二区三区| 日日夜夜操网爽| 可以在线观看毛片的网站| 麻豆一二三区av精品| 99国产精品99久久久久| 中文在线观看免费www的网站| 久久久久精品国产欧美久久久| 国产精品 欧美亚洲| 精品久久久久久成人av| 欧美丝袜亚洲另类 | 国产成人欧美在线观看| 欧美3d第一页| 久久久久国产一级毛片高清牌| 成人鲁丝片一二三区免费| 熟女少妇亚洲综合色aaa.| 免费在线观看亚洲国产| 真人一进一出gif抽搐免费| 亚洲人成电影免费在线| 中文字幕精品亚洲无线码一区| 在线免费观看不下载黄p国产 | 亚洲av成人精品一区久久| 免费在线观看日本一区| 脱女人内裤的视频| 国产精品野战在线观看| 亚洲在线观看片| 亚洲av成人一区二区三| 亚洲欧美日韩东京热| 成人高潮视频无遮挡免费网站| 日韩精品中文字幕看吧| 国产精品久久久久久久电影 | 亚洲av成人不卡在线观看播放网| 国产野战对白在线观看| 99re在线观看精品视频| 久久久成人免费电影| 国产精品一及| 欧美日韩中文字幕国产精品一区二区三区| 俄罗斯特黄特色一大片| 国产精品自产拍在线观看55亚洲| 51午夜福利影视在线观看| 亚洲国产精品成人综合色| 成人无遮挡网站| 最近最新免费中文字幕在线| 精品一区二区三区视频在线 | 又爽又黄无遮挡网站| 在线播放国产精品三级| 亚洲在线观看片| 免费在线观看视频国产中文字幕亚洲| 成人高潮视频无遮挡免费网站| 女同久久另类99精品国产91| 欧美日韩黄片免| 嫩草影视91久久| 2021天堂中文幕一二区在线观| 亚洲美女视频黄频| 深夜精品福利| 床上黄色一级片| 欧美在线一区亚洲| 国产欧美日韩一区二区精品| 亚洲人成伊人成综合网2020| 国产97色在线日韩免费| 午夜福利成人在线免费观看| 国产综合懂色| 欧美日韩国产亚洲二区| 亚洲国产精品合色在线| 亚洲专区国产一区二区| 精品电影一区二区在线| 18禁黄网站禁片免费观看直播| 久久婷婷人人爽人人干人人爱| 他把我摸到了高潮在线观看| 99精品欧美一区二区三区四区| 国产午夜精品久久久久久| 麻豆国产97在线/欧美| 听说在线观看完整版免费高清| 久久久久久久精品吃奶| 久久午夜亚洲精品久久| 99热6这里只有精品| 特大巨黑吊av在线直播| 欧美一级a爱片免费观看看| 无限看片的www在线观看| 中文亚洲av片在线观看爽| 日本与韩国留学比较| 久久精品夜夜夜夜夜久久蜜豆| 久久久久久久久久黄片| 桃红色精品国产亚洲av| 丝袜人妻中文字幕| 热99re8久久精品国产| 国内久久婷婷六月综合欲色啪| 天堂av国产一区二区熟女人妻| 国产精品99久久99久久久不卡| 欧美日韩黄片免| av中文乱码字幕在线| 他把我摸到了高潮在线观看| 成在线人永久免费视频| 一边摸一边抽搐一进一小说| 亚洲成人久久爱视频| 久久精品国产99精品国产亚洲性色| 精品午夜福利视频在线观看一区| 欧美一级a爱片免费观看看| 两性午夜刺激爽爽歪歪视频在线观看| 精品国产亚洲在线| 国产成人系列免费观看| 久久精品影院6| 国产精品女同一区二区软件 | 免费看日本二区| 午夜精品一区二区三区免费看| 两性午夜刺激爽爽歪歪视频在线观看| 国产午夜福利久久久久久| 91av网一区二区| 国产欧美日韩精品亚洲av| 日韩av在线大香蕉| 黄色片一级片一级黄色片| 丰满人妻熟妇乱又伦精品不卡| 香蕉久久夜色| 亚洲精品在线美女| 美女免费视频网站| 天堂动漫精品| 一个人观看的视频www高清免费观看 | 免费看a级黄色片| 亚洲激情在线av| 男女之事视频高清在线观看| 国产淫片久久久久久久久 | 我的老师免费观看完整版| 国内揄拍国产精品人妻在线| or卡值多少钱| 毛片女人毛片| 美女扒开内裤让男人捅视频| 国产亚洲精品综合一区在线观看| 精品国产超薄肉色丝袜足j| 国产一区在线观看成人免费| 波多野结衣高清作品| 99久久无色码亚洲精品果冻| tocl精华| 午夜久久久久精精品| 亚洲va日本ⅴa欧美va伊人久久| 久久精品人妻少妇| 在线免费观看的www视频| 最近最新中文字幕大全免费视频| 可以在线观看的亚洲视频| 黄色丝袜av网址大全| 天堂av国产一区二区熟女人妻| 黑人巨大精品欧美一区二区mp4| 亚洲欧美日韩无卡精品| 亚洲精品国产精品久久久不卡| 欧美成人一区二区免费高清观看 | 国产三级中文精品| 亚洲美女视频黄频| 嫩草影院精品99| 久久九九热精品免费| 蜜桃久久精品国产亚洲av| 欧美日本视频| 免费在线观看影片大全网站| 少妇丰满av| 露出奶头的视频| 色精品久久人妻99蜜桃| 最新在线观看一区二区三区| 国产成人av激情在线播放| 白带黄色成豆腐渣| 午夜福利在线在线| 黄片小视频在线播放| 一边摸一边抽搐一进一小说| 精品午夜福利视频在线观看一区| 日韩欧美在线乱码| 国产99白浆流出| 亚洲片人在线观看| 90打野战视频偷拍视频| 国产欧美日韩一区二区精品| 国内久久婷婷六月综合欲色啪| 又黄又爽又免费观看的视频| 亚洲成人精品中文字幕电影| av在线天堂中文字幕| 美女 人体艺术 gogo| 国产探花在线观看一区二区| 亚洲熟女毛片儿| 少妇丰满av| 欧美激情在线99| 免费看日本二区| 特级一级黄色大片| 日本与韩国留学比较| 视频区欧美日本亚洲| 一级作爱视频免费观看| 在线播放国产精品三级| 欧美日韩瑟瑟在线播放| 99国产极品粉嫩在线观看| 麻豆国产97在线/欧美| 午夜精品在线福利| 午夜久久久久精精品| 国产黄片美女视频| av欧美777| 国产高清有码在线观看视频| e午夜精品久久久久久久| 99精品在免费线老司机午夜| 手机成人av网站| 一a级毛片在线观看| 日本免费a在线| 国产成人一区二区三区免费视频网站| 国产成人av激情在线播放| 国产午夜精品久久久久久| 高清毛片免费观看视频网站| 国产69精品久久久久777片 | 19禁男女啪啪无遮挡网站| 最近在线观看免费完整版| 久久久久久久久免费视频了| 黑人巨大精品欧美一区二区mp4| 久久99热这里只有精品18| 啪啪无遮挡十八禁网站| 亚洲av电影不卡..在线观看| 一本综合久久免费| 国产三级在线视频| 国产精品av久久久久免费| 亚洲人成伊人成综合网2020| 国产成人精品久久二区二区免费| 久久久久久九九精品二区国产| 精品乱码久久久久久99久播| 国产成人影院久久av| 校园春色视频在线观看| 757午夜福利合集在线观看| 亚洲欧美日韩无卡精品| av在线天堂中文字幕| 国产97色在线日韩免费| 亚洲av成人一区二区三| 免费看a级黄色片| 精品久久久久久久毛片微露脸| 久久久国产成人免费| 亚洲欧洲精品一区二区精品久久久| 国产亚洲av高清不卡| 国产精品久久久人人做人人爽| 狠狠狠狠99中文字幕| 欧美成人免费av一区二区三区| 老司机深夜福利视频在线观看| 日韩成人在线观看一区二区三区| 国产黄a三级三级三级人| 黄片大片在线免费观看| 日本一本二区三区精品| 久久精品91蜜桃| 亚洲18禁久久av| 久久九九热精品免费| 99热精品在线国产| 黄色 视频免费看| 免费高清视频大片| 1024手机看黄色片| 真实男女啪啪啪动态图| 一区二区三区激情视频| 久久天堂一区二区三区四区| av视频在线观看入口| 精品99又大又爽又粗少妇毛片 | 不卡一级毛片| 午夜免费观看网址| 桃红色精品国产亚洲av| xxx96com| 男人舔女人的私密视频| 变态另类丝袜制服| tocl精华| 久久久久久久久中文| 日韩中文字幕欧美一区二区| www.999成人在线观看| 99精品久久久久人妻精品| 久久久精品大字幕| 麻豆久久精品国产亚洲av| 哪里可以看免费的av片| 亚洲色图 男人天堂 中文字幕| 精品一区二区三区av网在线观看| 国内精品美女久久久久久| 十八禁网站免费在线| 18禁黄网站禁片午夜丰满| netflix在线观看网站| av天堂在线播放| 男女之事视频高清在线观看| 精品久久久久久成人av| 三级男女做爰猛烈吃奶摸视频| 88av欧美| 热99re8久久精品国产| 久久精品亚洲精品国产色婷小说| 国产真人三级小视频在线观看| 日韩高清综合在线| 99精品在免费线老司机午夜| 精品人妻1区二区| 老汉色av国产亚洲站长工具| 在线免费观看不下载黄p国产 | 国内少妇人妻偷人精品xxx网站 | 校园春色视频在线观看| 日韩中文字幕欧美一区二区| 天堂动漫精品| 国产成人一区二区三区免费视频网站| 欧美乱码精品一区二区三区| 国产乱人视频| 黄色视频,在线免费观看| 人妻久久中文字幕网| 亚洲专区国产一区二区| 中文字幕人妻丝袜一区二区| 国产淫片久久久久久久久 | 久久精品aⅴ一区二区三区四区| 黄片大片在线免费观看| 国产激情偷乱视频一区二区| 亚洲成人精品中文字幕电影| 少妇裸体淫交视频免费看高清| 女人被狂操c到高潮| 国产成+人综合+亚洲专区| 色在线成人网| 香蕉丝袜av| 婷婷丁香在线五月| 日韩国内少妇激情av| 午夜福利18| 亚洲精品中文字幕一二三四区| 久久精品国产99精品国产亚洲性色| 免费无遮挡裸体视频| 国产主播在线观看一区二区| 青草久久国产| 99久久99久久久精品蜜桃| 一区福利在线观看| tocl精华| 中文资源天堂在线| 日本 av在线| 欧美成人一区二区免费高清观看 | АⅤ资源中文在线天堂| xxxwww97欧美| 黄色成人免费大全| 国产私拍福利视频在线观看| 18禁黄网站禁片午夜丰满| 欧美精品啪啪一区二区三区| 国产欧美日韩一区二区三| 99在线视频只有这里精品首页| 中文字幕久久专区| 亚洲 国产 在线| 欧美成人性av电影在线观看| 国产aⅴ精品一区二区三区波| www.自偷自拍.com| 亚洲欧美日韩卡通动漫| 九色国产91popny在线| 久久精品人妻少妇| 亚洲七黄色美女视频| 男女那种视频在线观看| 婷婷精品国产亚洲av在线| 两个人视频免费观看高清| 亚洲精品456在线播放app | 国产av在哪里看| 久久亚洲真实| 可以在线观看毛片的网站| 欧美av亚洲av综合av国产av| 亚洲aⅴ乱码一区二区在线播放| 国产探花在线观看一区二区| 欧美在线黄色| 欧美成狂野欧美在线观看| 国产伦一二天堂av在线观看| 色吧在线观看| 别揉我奶头~嗯~啊~动态视频| 无限看片的www在线观看| 欧美黄色片欧美黄色片| 美女高潮的动态| 国产极品精品免费视频能看的| 综合色av麻豆| 制服人妻中文乱码| 日本与韩国留学比较| 国产黄色小视频在线观看| 国产成人av激情在线播放| 色在线成人网| 久久久久久久久久黄片| 欧美黄色淫秽网站| 黑人巨大精品欧美一区二区mp4| 久久久久久大精品| 久久伊人香网站| 国产精品久久久久久亚洲av鲁大| 啪啪无遮挡十八禁网站| 波多野结衣巨乳人妻| 午夜免费观看网址| av片东京热男人的天堂| 亚洲中文字幕日韩| 制服丝袜大香蕉在线| 国产成人av激情在线播放| 一级a爱片免费观看的视频| 午夜精品久久久久久毛片777| 在线十欧美十亚洲十日本专区| 国产av不卡久久| 欧美一级毛片孕妇| 亚洲 国产 在线| 国产成人影院久久av| 国产精品99久久久久久久久| 亚洲18禁久久av| 蜜桃久久精品国产亚洲av| 国产精品影院久久| 午夜免费激情av| 天天一区二区日本电影三级| 九色成人免费人妻av| av黄色大香蕉| 久久国产乱子伦精品免费另类| 一本一本综合久久| 又黄又爽又免费观看的视频| 国产精品九九99| 日本三级黄在线观看| av中文乱码字幕在线| 国产亚洲av嫩草精品影院| 国产精品乱码一区二三区的特点| 久久精品影院6| 欧美中文综合在线视频| 亚洲欧美日韩东京热| 岛国视频午夜一区免费看| 成熟少妇高潮喷水视频| 午夜福利在线在线| 国产亚洲av嫩草精品影院| 欧美日韩瑟瑟在线播放| 国产一区二区在线av高清观看| 国产久久久一区二区三区| 国产av在哪里看| 精品一区二区三区视频在线 | 亚洲午夜精品一区,二区,三区| 欧美一区二区国产精品久久精品| 久久午夜综合久久蜜桃| 人人妻人人澡欧美一区二区| 十八禁人妻一区二区| 香蕉久久夜色| 国产三级黄色录像| 亚洲国产精品久久男人天堂| 国产野战对白在线观看| 可以在线观看的亚洲视频| 国产亚洲精品久久久久久毛片| 国产高清有码在线观看视频| 日韩欧美在线乱码| 中文字幕人妻丝袜一区二区| 国产成人啪精品午夜网站| av天堂在线播放| 一级作爱视频免费观看| 一级黄色大片毛片| 免费人成视频x8x8入口观看| 久久精品国产综合久久久| 男女午夜视频在线观看| 成人av在线播放网站| 在线观看免费视频日本深夜| 亚洲av熟女| 一本综合久久免费| 午夜福利免费观看在线| 久久久精品大字幕| 黄色女人牲交| 成人三级做爰电影| 女人高潮潮喷娇喘18禁视频| 1024手机看黄色片| 午夜两性在线视频| 中亚洲国语对白在线视频| 在线十欧美十亚洲十日本专区| 欧美性猛交╳xxx乱大交人| 国产精品野战在线观看| 男人舔女人下体高潮全视频| 首页视频小说图片口味搜索| 日韩精品青青久久久久久| 国产真实乱freesex| 亚洲精品在线美女| 精品久久久久久久末码| 又黄又爽又免费观看的视频| 欧美性猛交╳xxx乱大交人| 天堂av国产一区二区熟女人妻| 波多野结衣高清作品| 一本精品99久久精品77| 少妇丰满av| 亚洲第一欧美日韩一区二区三区| av天堂在线播放| 男人的好看免费观看在线视频| 国产精品一区二区精品视频观看| 国产成人精品久久二区二区91| 又黄又粗又硬又大视频| 99国产综合亚洲精品| 91在线观看av| 淫秽高清视频在线观看| 精品久久久久久久人妻蜜臀av| 国产高清视频在线观看网站| 日本一本二区三区精品| 国产精品久久久久久精品电影| 欧美色欧美亚洲另类二区| 国产精品影院久久| 亚洲人成伊人成综合网2020| 999久久久国产精品视频| 亚洲国产色片| 欧美日韩精品网址| 国产高清有码在线观看视频| 无限看片的www在线观看| 噜噜噜噜噜久久久久久91| 小蜜桃在线观看免费完整版高清| 琪琪午夜伦伦电影理论片6080| 国产在线精品亚洲第一网站| 亚洲,欧美精品.| 最新美女视频免费是黄的| 国产91精品成人一区二区三区| 天堂影院成人在线观看| 国产精品久久久久久精品电影| 在线播放国产精品三级| 男女做爰动态图高潮gif福利片| 日韩欧美在线二视频| 黄色女人牲交| 亚洲第一电影网av| 久久久成人免费电影| 国产v大片淫在线免费观看| 精华霜和精华液先用哪个| 中出人妻视频一区二区| 精华霜和精华液先用哪个| 中出人妻视频一区二区| 91av网一区二区| 精品日产1卡2卡| 一a级毛片在线观看| 老司机福利观看| 日韩 欧美 亚洲 中文字幕| 精品久久蜜臀av无| 丁香欧美五月| x7x7x7水蜜桃| 精品电影一区二区在线| 国产成人aa在线观看| 国产乱人视频| 免费在线观看亚洲国产| 免费看a级黄色片| 亚洲一区高清亚洲精品| 搡老岳熟女国产| www.精华液| 久久天堂一区二区三区四区| 一本精品99久久精品77| 亚洲av免费在线观看| 中文字幕久久专区| 国产av不卡久久| 波多野结衣巨乳人妻| 综合色av麻豆| 好看av亚洲va欧美ⅴa在| 91av网站免费观看| 免费看光身美女| 免费搜索国产男女视频| av福利片在线观看| 99riav亚洲国产免费| 一区二区三区激情视频| tocl精华| 男人舔奶头视频| 国产亚洲欧美98| 啦啦啦免费观看视频1| 美女扒开内裤让男人捅视频| 久久天堂一区二区三区四区| 欧美一级a爱片免费观看看| 亚洲精品美女久久av网站| 国产1区2区3区精品| 国产精品av久久久久免费| 亚洲最大成人中文| 亚洲五月天丁香| 亚洲中文字幕日韩| 亚洲欧美日韩高清专用| 18禁观看日本| aaaaa片日本免费| 免费av不卡在线播放| 国产精华一区二区三区| 成人av一区二区三区在线看| 美女 人体艺术 gogo| 欧美av亚洲av综合av国产av| 法律面前人人平等表现在哪些方面| 免费电影在线观看免费观看| 日韩大尺度精品在线看网址| 国产一区二区激情短视频| 日韩欧美在线乱码| 一个人免费在线观看的高清视频| 熟妇人妻久久中文字幕3abv| 老鸭窝网址在线观看| 久久精品91蜜桃| 国产麻豆成人av免费视频| 天天躁狠狠躁夜夜躁狠狠躁| 熟女少妇亚洲综合色aaa.| 99久久精品热视频| 午夜精品一区二区三区免费看| 视频区欧美日本亚洲| 又黄又粗又硬又大视频| 色精品久久人妻99蜜桃| 悠悠久久av|